Avadel Pharmaceuticals PLC
AVDL18.830USD
+0.130+0.70%
Fechamento 11/11, 16:00（ET）Cotações atrasadas em 15 min
1.83BValor de mercado
PerdaP/L TTM
Mais detalhes de Avadel Pharmaceuticals PLC Empresa
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Informações de Avadel Pharmaceuticals PLC
Código da empresaAVDL
Nome da EmpresaAvadel Pharmaceuticals PLC
Data de listagemJan 16, 1952
CEOMr. Gregory J. (Greg) Divis, Jr.
Número de funcionários188
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 16
EndereçoBlock 10-1 Blanchardstown Corporate Park
CidadeDUBLIN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísIreland
Código postal15
Telefone35319015201
Sitehttps://www.avadel.com/
Código da empresaAVDL
Data de listagemJan 16, 1952
CEOMr. Gregory J. (Greg) Divis, Jr.
Executivos da empresa Avadel Pharmaceuticals PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 3 de mar
Moeda: USDAtualizado em: seg, 3 de mar
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Por RegiãoUSD
Nome
Receita
Proporção
United States
22.33M
100.00%
Ireland
0.00
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Distribuição de ações
Atualizado em: ter, 11 de nov
Atualizado em: ter, 11 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
11.40%
Brandes Investment Partners, L.P.
6.64%
Two Seas Capital LP
6.30%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
5.66%
Outro
63.88%
Investidores
Investidores
Proporção
Janus Henderson Investors
11.40%
Brandes Investment Partners, L.P.
6.64%
Two Seas Capital LP
6.30%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
5.66%
Outro
63.88%
Tipos de investidores
Investidores
Proporção
Investment Advisor
31.44%
Investment Advisor/Hedge Fund
29.01%
Hedge Fund
24.24%
Individual Investor
4.79%
Venture Capital
3.44%
Research Firm
1.32%
Pension Fund
0.51%
Bank and Trust
0.36%
Insurance Company
0.03%
Outro
4.85%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
382
84.18M
86.25%
-22.86M
2025Q2
375
87.44M
90.23%
-20.44M
2025Q1
377
85.31M
88.05%
-24.78M
2024Q4
354
86.56M
89.59%
-16.46M
2024Q3
334
81.87M
84.98%
-15.41M
2024Q2
299
81.11M
84.30%
-2.77M
2024Q1
258
76.98M
80.25%
+5.42M
2023Q4
226
62.92M
70.15%
-3.93M
2023Q3
220
60.11M
69.62%
-5.86M
2023Q2
213
57.67M
66.98%
-1.24M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
11.13M
11.46%
-2.46M
-18.10%
Jun 30, 2025
Brandes Investment Partners, L.P.
6.49M
6.68%
+820.47K
+14.48%
Jun 30, 2025
Two Seas Capital LP
6.16M
6.34%
+1.21M
+24.43%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.98M
6.16%
+1.29M
+27.56%
Jun 30, 2025
The Vanguard Group, Inc.
5.54M
5.71%
+1.66M
+42.73%
Jun 30, 2025
Tontine Asset Management, LLC
5.18M
5.33%
-950.54K
-15.51%
Jun 30, 2025
Polar Capital LLP
4.00M
4.12%
-356.63K
-8.19%
Jun 30, 2025
Kotler (Kevin)
3.72M
3.83%
-1.01M
-21.37%
Feb 12, 2024
Vivo Capital, LLC
2.68M
2.76%
--
--
Jun 30, 2025
Wealth Effects LLC
2.35M
2.43%
-14.30K
-0.60%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Invesco Pharmaceuticals ETF
2.75%
Innovator IBD 50 Fund ETF
2.64%
iShares Neuroscience and Healthcare ETF
2.45%
SPDR S&P Pharmaceuticals ETF
1.82%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.37%
iShares U.S. Pharmaceuticals ETF
0.55%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.36%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.19%
JPMorgan Fundamental Data Science Small Core ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.15%
Ver Mais
Invesco Pharmaceuticals ETF
Proporção2.75%
Innovator IBD 50 Fund ETF
Proporção2.64%
iShares Neuroscience and Healthcare ETF
Proporção2.45%
SPDR S&P Pharmaceuticals ETF
Proporção1.82%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.37%
iShares U.S. Pharmaceuticals ETF
Proporção0.55%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporção0.36%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.19%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.16%
Invesco Nasdaq Biotechnology ETF
Proporção0.15%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
